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Abstract
Pompe disease (PD) is a rare neuromus-
cular disorder caused by a deficiency of the
enzyme acid alpha-glucosidase. There are
three forms of PD depending on the age at
onset and clinical severity. PD causes
involvement of different organ systems,
such as the heart, musculoskeletal system,
and respiratory system. As of today, enzyme
replacement therapy represents the main
therapeutic tool for PD. Rehabilitation is an
integral part of a multidisciplinary approach
to this pathology. The goal of the present
review is to find scientific evidence for the
rehabilitative approach to PD, with respect
to both the infantile- and adult-onset forms.
A systematic literature review was made
using the following databases: Pubmed,
Pedro, Cochrane Library, EDS Base Index,
Trip, and Cinhal. Randomized controlled
trials or cohort studies with a sample popu-
lation of at least six subjects were retrieved.
The PICO method was used to formulate
the clinical query. The search resulted in
1665 articles. Of these, four cohort studies
were subjected to the final phase of the
review. Three studies regarded inspiratory
muscle training with a threshold, while the
fourth study analyzed the effectiveness of
therapeutic, aerobic, and reinforcement
exercises. Inspiratory muscle training with a
threshold increases the pressures generated
during inhalation. Aerobic exercise is capa-
ble of increasing patients’ muscular
endurance and performance. To date, how-
ever, rehabilitative treatment for patients
with PD has no validation in evidence-
based medicine. Further studies, possibly
with a larger sample size and higher quality
are necessary to confirm the effectiveness
of rehabilitation in patients with PD.
Introduction
Pompe disease (PD), also referred to as
acid maltase deficiency (AMD) or glycogen
storage disease type II (GSDII), is a rare
autosomal recessive neuromuscular disorder
caused by a deficiency of the lysosomal
enzyme acid alpha-glucosidase (GAA).1 A
shortage of GAA causes a toxic accumula-
tion of glycogen in many tissues, and in par-
ticular in smooth, skeletal, and cardiac mus-
cle. The incidence of the syndrome is vari-
able and depends upon ethnicity and geo-
graphical area. It is more prevalent among
African-Americans (1:14000)2 and much
less on the European continent (1:40000).3
From the etiological perspective, PD is
caused by different mutations of the genes
that interact to synthesize GAA, with a con-
sequent lysosomal storage of glycogen. The
mutations most studied in the literature are
c.525delT,4 c.2237G > A,5 and c.-32-13T >
G.6 An increasing number of studies have
dealt with the role of autophagy in the gene-
sis of PD. Autophagy, or ‘self-eating’, is an
extremely complex lysosomal degradation
process controlled by a network of multiple
genes. The main function of this mechanism
is to eliminate organelles and obsolete pro-
tein aggregates in order to protect the cell
from the stress of oxidation and/or nutrition-
al deficiency. Changes in this mechanism are
linked to various neurodegenerative patholo-
gies involving accumulation, such as PD,
and in the generation of some forms of
tumors with cellular senescence.7-10
PD is classified into two forms accord-
ing to the age of onset. The infantile form
(infantile-onset Pompe disease - IOPD)
clinically arises in the first year of life,
while the adult form (late-onset Pompe dis-
ease - LOPD) appears between 29 and 33
years of age.11 IOPD in turn is classified
into two types depending on organ involve-
ment and degree of myopathy: the classical
form (classic IOPD), which usually leads to
death due to cardiac arrest within the first
year of life, and the non-classical form
(non-classic IOPD), which is characterized
by cardiomegaly and muscular weakness,
with consequent respiratory insufficiency.
Patients affected by non-classic IOPD are
not faced with death due to cardiac arrest
within the first year of life but generally do
not survive beyond early childhood due to
serious respiratory problems.
PD damages different organ systems in
the body. With respect to the respiratory
system, patients develop progressive respi-
ratory insufficiency due to weakness of the
diaphragm and intercostal muscles. Effects
on the musculoskeletal system include
insufficiency of the pelvic girdle muscles,
insufficiency of the neck flexor muscles,
scapulothoracic winging, and decreased
strength of the abdominal wall.12
Scoliosis13 and decreased bone density14 are
frequently diagnosed in children with PD.
The cardiac muscle is frequently affected in
all forms of PD and cases of serious
arrhythmias or Wolff-Parkinson-White syn-
dromes have been reported in the
literature.15 Recent studies have highlighted
cases of pre-symptomatic hyperCKemia.16
Finally, several studies indicate that con-
genital molecular alterations in neuromus-
cular diseases, like PD, promote cognitive
dysfunctions.17,18
In 2015, early diagnosis of the pediatric
forms of PD was included in the
Recommended Uniform Screening Panel
(RUSP) by the national study commission
on rare and hereditary neonatal disorders.19
In particular, the commission recommended
an evaluation of GAA enzyme activity via a
dried blood spot (DBS) test. In cases of
insufficient or nonexistent activity, an ana-
lytical examination should be made of the
systems involved in order to identify the
genetic and pathological type. The same
algorithm can be applied to the late-onset
forms. With regard to treatment, until a few
years ago PD was only treated via support-
ive care. A real turning point in the treat-
ment of PD came in 2007, when enzyme
replacement therapy (ERT) was approved
for patients with infantile forms of PD. In
2010 ERT was also approved for the late-
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onset form. In ERT, an extract of recombi-
nant human GAA (also partially extracted
from animals) is administered intravenous-
ly. This enzyme breaks down the accumula-
tion of glycogen, particularly on the cardiac
muscle.20 ERT has led to a clear decrease in
short-term mortality and an improvement in
respiratory and cardiac disorders in patients
with PD.20-24 In particular, significant
increases have been reported in the time
spent by patients without a ventilator, there-
by allowing for greater autonomy and the
achievement of new motor abilities.24,25
Simultaneous with the benefits of managing
vital functions in PD, the change in pheno-
typic expression introduced by ERT has led
to the appearance of additional clinical
problems related primarily to rehabilitation.
The clinical picture of these patients (with
either IOPD or LOPD) is characterized by
muscular weakness, with the appearance of
facial muscle asthenia, ptosis, insufficiency
of the hip flexors and ankle dorsiflexors,
difficulty walking, posture disorders, and
scoliosis.13,26
Based on the above, it is clear that the
need for a rehabilitative framework for
patients with PD represents a gold standard
in managing this syndrome. To date, differ-
ent authors have developed general guide-
lines for physiotherapy programs for PD.
Clinton et al.,27 for example, recommend
team management that integrates interven-
tions by cardiologists, pulmonologists,
physiatrists, physiotherapists and occupa-
tional therapists (Table 1 shows all the inter-
ventions proposed). Despite this, clinical
evidence for the rehabilitative management
of this syndrome is rare. The scope of the
present review is to look for better available
EBM regarding rehabilitation in patients
with PD in order to establish practical rec-
ommendations for clinical conduct.
Materials and Methods
A systematic review of the literature
was made using the following databases:
Pubmed, Pedro, Cinhal, Cochrane Library,
EDS Base Index, and Trip. The databases
were accessed in October 2018. The PICO
method was used to formulate the clinical
query according to the following parame-
ters:28
- Population: PD patients
- Intervention: physiotherapy
- Comparison: inactive control groups
- Outcome: respiratory function improve-
ments, improvements in range of
motion/muscular strength 
Inclusion criteria and keywords
Articles considered valid for the review
addressed randomized controlled trials
(RCT) or cohort studies relating to rehabili-
tation in patients with PD, with no time
limit, but with a study sample of at least six
subjects. Only articles in English were
selected. Table 2 summarizes the keywords
used to perform the search.
Results
A total of 1665 results emerged from
the search. Figure 1 shows the process to
progressively select the articles found. With
an initial screening, all results reported mul-
tiple times in the database (437 articles)
were eliminated. Following this, a second-
ary screening of the title and abstract was
made, resulting in the elimination of (a)
article not dealing with the rehabilitation in
patients with PD and (b) types of publica-
tions different from what was stated in the
inclusion criteria (conference proceedings,
extracts from textbooks, single expert opin-
ions, animal-based studies). This second
screening allowed an additional 1210
results to be eliminated. Therefore, the full-
text version of a total of 18 articles was
assessed. These results were divided thus: 4
studies on individual cohorts, 3 case series,
5 case reports, 3 exploratory studies, and 3
literature reviews addressing the diagnostic
procedure for PD.
The 4 studies in the first group were
therefore admitted to the final phase of the
review. From the detailed analysis of these
articles, two approaches to rehabilitation in
patients with PD were identified: respirato-
ry muscle rehabilitation and physical activ-
ity. The main data used in all the studies
included are reported in Table 3.29-32
Re-education of the respiratory
muscles
A total of 3 studies29-31 dealt with the
management of respiratory muscles in
patients with PD. Chest physical therapy
was always practiced as an adjuvant therapy
to ERT. All the studies examined were sin-
gle cohorts. The population studied by
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Table 1. Evaluation and rehabilitation of PD according to the recommendations by Clinton et al.27
Clinical recommendations
Preliminary assessment with a pulmonologist or cardiologist before performing aerobic exercises or physiotherapy
Evaluate 6MWT at time 0
Include in rehabilitation programs walking, treadmill, use of the cyclette, the hydrokinetic therapy, swimming, muscle strengthening
Avoid excessively tiring exercises; avoid immobility
Give emphasis to aerobic exercises
Instruct the patient to monitor heart rate and breathing during exercise
Use preventive braces for contractures while the patient is in a wheelchair, and adequate supports when standing
Evaluate corrective surgery for scoliosis above 30-40°
Table 2. Keyword used for the search.
Keyword 1                                                                                   Keyword 2                                                 Boolean operator
Pompe Disease                                                                                                   Physiotherapy                                                                         AND/OR
Pompe Disease                                                                                                   Rehabilitation                                                                         AND/OR
Pompe Disease                                                                                                    Management                                                                          AND/OR
Glycogen Storage Disease Type 2                                                                   Physiotherapy                                                                         AND/OR
Glycogen Storage Disease Type 2                                                                   Rehabilitation                                                                         AND/OR










Jevnikar et al.,29 and Aslan et al.,31 was
composed of patients with LOPD, while
only the article by Smith30 regarded a pop-
ulation with IOPD, which was already
severely compromised from the respiratory
point of view (patients ventilated for multi-
ple hours per day). With regard to the inter-
vention proposed, Jevnikar29 followed a
protocol of inspiratory muscle training
against fixed resistance (threshold). In par-
ticular, the patient was first studied with
spirometry and then coached to perform 45
minutes of daily training: 15 minutes reach-
ing 30% of the maximal inspiratory pres-
sures (MIP) registered and the remaining
time in deep breathing. Smith,30 instead,
developed a protocol in which patients with
IOPD followed inspiratory training three
times per week in preparation for surgery
for diaphragm gene therapy. Using modi-
fied equipment (Threshold PEP or Accu-
PEEP), patients followed 3-4 series of 6-10
active inhalations during which the maxi-
mum tolerated volume should be reached
while maintaining SpO2>92%. Finally,
Aslan developed an inspiratory muscle
training program with a threshold lasting 8
weeks in which the 8 patients recruited
were asked to perform the exercise two
times per day.31 The level of required inspi-
ratory pressure started at 30% of MIP regis-
tered with spirometry, increasing by 2 cm
H2O each week.
With regard to the outcomes recorded,
the levels of MIP were used in all studies,29-
31 while only the study by Smith30 exam-
ined volume, flux, and post-inhalation com-
pensation time with a threshold (at some
points excluding the mechanical ventilation
in the children studied). In addition, the
electromyographic response of the
diaphragm after training was evaluated.
Lastly, the study by Aslan31 assessed the
values of peak cough flow (PCF), forced
vital capacity (FVC), the FVC/forced expi-
ratory volume ratio in 1 second (FEV1),
quality of life using the Nottingham Health
Profile (NHP), and quality of sleep using
the Pittsburgh Sleep Quality Index (PSQI).
The follow-up period varied among the dif-
ferent studies: up to 24 months in the trial
by Jevnikar,29 one year in the study by
Smith,30 and 24 weeks in the study by
Aslan.31
Finally, with respect to the results
obtained, the study by Jevnikar29 highlight-
ed a significant increase in MIP values, in
agreement with what was demonstrated by
Aslan.31 This data appears to contrast with
what emerged from the study by Smith,30 in
which the pressure values did not change
after the intervention. However, these val-
ues refer to a pediatric population in part
already fully dependent on mechanical ven-
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Figure 2. MIP values after threshold training according to Jevnikar29 and Aslan31 studies.
Figure 1. Selection of articles for the review.










tilation. With regard to the indicators of suc-
cess, Smith30 found an increase in the com-
pensatory response to threshold at only 180
days, with an increase in maximum volun-
tary ventilation in subjects and evidence of
diaphragm activity on the electromyogra-
phy. Finally, Aslan31 reported no modifica-
tion in quality of sleep or quality of life at
the end of the proposed protocol. Figure 2
shows a comparison of MIP values between
Aslan31 and Jevnikar.29
Aerobic exercise and general physi-
cal activity
Only one article addressed protocols for
general physical exercise in patients with
PD.32 The study, already presented previ-
ously at the sixth European innovation sum-
mit on PD,33 was conducted on a population
of 25 patients with LOPD (23 completed
the study), all of whom were undergoing
ERT. The rehabilitation program, which
lasted 12 weeks, included 36 sessions of
aerobic training using a cycle ergometer,
active resistance exercises (weights/mat
activities), and core stability training. The
authors evaluated the following as outcome
measures: fatigue (using the Fatigue
Severity Scale, FSS), plasma values of cre-
atine kinase (CK; every two weeks), oxygen
consumption during exercise (maximal
oxygen uptake peak − VO2 peak − and max-
imum work capacity − WMAX), maximum
ventilatory threshold (VT), tolerance to
exertion (using the Borg scale and six
minute test), duration of hold in core stabil-
ity exercises, muscular function (using the
quick motor function test), and body com-
position (using dual X-ray absorptiometry,
DXA). The authors report statistically sig-
nificant increases in muscular endurance
indices (VO2 peak, WMAX, and VT), an
increase in the duration of hold in core sta-
bility exercises, and the muscular strength
of some groups (hip flexors, shoulder
abductors). All the other outcomes evaluat-
ed were stable. 
Discussion
The present review complies with the
standards defined by the PRISMA state-
ment for methodological quality of a litera-
ture review.34 From what was illustrated
above, rehabilitation in the management of
patients with PD is a useful tool to strength-
en the effects of ERT, contributing to the
patient’s greater respiratory and muscular
compliance. In fact, in all studies examined,
the two treatments were made simultane-
ously.29-32 However, this topic has been
undervalued by the scientific literature.
Indeed, from our review, no RCT or cohort
studies with controlled groups were found.
The studies that were found were only
experiments with single cohorts, with a very
small sample (8-9 subjects for the respirato-
ry rehabilitation studies, 23 in the only
motor re-education study). This obviously
represents the main limitation and source of
bias of the present review, and in general, of
studies on rehabilitation in patients with
rare neuromuscular pathologies.35-39 With
regard to indications deriving from our
review, rehabilitation methods aimed at
reinforcing the respiratory muscles seem to
increase MIP levels with a statistically sig-
nificant difference,29,31 while only one pub-
lication30 deviates from this trend. It should
be mentioned that the study in question
regarded a notably different population of
patients with respect to both age of onset
(IOPD) and ventilatory impairment (5
patients already depended on mechanical
ventilation for most of the day). The main
changes observed in this case were reported
in the follow-up at 180 days (increase in
flows and volumes of inspiratory rehabilita-
tion after training). No other substantial
changes were described with respect to the
respiratory profile of the participants. The
validity of inspiratory training with a
threshold with level III evidence, represents
the greatest innovation in our study. The
guidelines currently drafted for PD advise
other therapeutic measures (management of
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Table 3. Summary of included studies.
Study                       Design             Participants    Intervention                                           Outcome measures
Jevnikar et al.29 2015       Single Cohort        n = 8                       Exp = ERT +respiratory                                         •    MIP, MEP
                                                                                                              45 min/day × 24 months                                                 muscle training with threshold
                                                                                                                                                                                                     •    Follow up: 0,3,6,9,12,24 month
                                                                                                                                                                                                   
Smith et al.30 2017           Single Cohort        n = 9                       Exp = ERT + respiratory muscle                          •    Inspired tidal volume (VT), 
                                                                                                              training with PEEP                                                           peak inspiratory flow (PIF),
                                                                                                              6/10 active breaths × 4 /day × 3 months                    inspiratory pressure (PI), 
                                                                                                                                                                                                            inspiratory time (TI), expiratory time (TE)
                                                                                                                                                                                                     •    Borg scale
                                                                                                                                                                                                     •    MIP
                                                                                                                                                                                                     •    Volume, flow and timing compensatory responses to 
                                                                                                                                                                                                            inspiratory loads were evaluated using Threshold
                                                                                                                                                                                                            training devices
                                                                                                                                                                                                     •    EMG
                                                                                                                                                                                                     •    Follow up =0, 90, 180, 365 day
Aslan et al.31 2016            Single Cohort        n = 9                       Exp = ERT + respiratory muscle training          •    MIP, Cough peak flow(PCF)
                                                                                                              with threshold                                                            •    Forced vital capacity (FVC), FVC/FEV1 
                                                                                                              15 min × 2 /day × 8 wk                                             •    HRQoL (Nottingham Health Profile)
                                                                                                                                                                                                     •    Sleep quality (Pittsburgh Sleep Quality Index -PSQI).
                                                                                                                                                                                                     •    Follow up = 0, 8,16, 24 wk
Van der Berg                    Single Cohort        n = 23                     Exp = standardized aerobic, resistance and      •    Fatigue severity scale 
et al.32 2015                                                                                          core stability exercises 3 /wk × 12 wk                 •    Serum CK 
                                                                                                                                                                                                     •    VO2 max and WMAX)
                                                                                                                                                                                                     •    Ventilator threshold (VT), 
                                                                                                                                                                                                     •    Borg scale and 6MWT 
                                                                                                                                                                                                     •    Resistance during core stability exercises, 
                                                                                                                                                                                                     •    Quick motor function test
                                                                                                                                                                                                     •    DXA
                                                                                                                                                                                                     •    Follow up = 0, 12, 24 wk










bronchial secretions via drainage tech-
niques, assistance coughing with an in-
exsufflator, continuous monitoring of sleep
problems with the C-pap machine).27,40
However, the need remains for new RCTs
with definitive EBM confirmation of these
pulmonary rehabilitation protocols. Finally,
with regard to the effectiveness of rehabili-
tative treatment based on aerobic and resist-
ance training, the data uncovered refer only
to a study by van Der Berg et al.33 The trend
of the sample studied shows a positive
effect on the strength and endurance of
some muscle groups, as well as on strength
parameters of the core stability muscles.
This seems to be confirmed in part by pre-
vious literature. Indeed, Kishnani et al.40
advise starting patients on mainly aerobic
rehabilitative activities immediately after
the general medical conditions are stabi-
lized, avoiding activities that excessively
stimulate the weakened muscle groups in
eccentric contractions. About this topic as
well, however, it is necessary to make a
deeper scientific investigation by carrying
out studies with greater evidence (RCTs)
and a larger sample. 
Conclusions
The present systematic literature review
highlights that no sufficient studies on the
methodological level exist today to support
rehabilitation in the management of patients
with PD. The cohort studies that are avail-
able suggest the use of inspiratory muscle
training with a threshold to increase average
MIP values (level III evidence) and rehabil-
itation programs based on physical aerobic
exercise. However, new, broader studies are
needed to definitively validate the above-
mentioned recommendations. 
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